

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

22 May 2020 (22.05.2020)



(10) International Publication Number

WO 2020/102558 A1

(51) International Patent Classification:

A61K 31/712 (2006.01) C12N 15/11 (2006.01)

A61K 31/7125 (2006.01) C12N 15/113 (2010.01)

C07H 21/02 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2019/061508

(22) International Filing Date:

14 November 2019 (14.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/767,123 14 November 2018 (14.11.2018) US

62/924,001 21 October 2019 (21.10.2019) US

(71) Applicant: IONIS PHARMACEUTICALS, INC.

[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: REVENKO, Alexey; 2855 Gazelle Ct., Carls-

bad, CA 92010 (US). MACLEOD, Robert, A.; 2855

Gazelle Ct., Carlsbad, CA 92010 (US). FREIER, Susan,

M.; 2855 Gazelle Ct., Carlsbad, CA 92010 (US).

(74) Agent: LIU, Jing et al.; Sheppard Mullin Richter & Hamp-

ton LLP, 650 Town Center Drive, 10th Floor, Costa Mesa,
CA 92626 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: MODULATORS OF FOXP3 EXPRESSION

(57) Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer. Certain embodiments provided herein are directed to potent and tolerable compounds and compositions useful for inhibiting FOXP3 expression, which can be useful for treating, preventing, ameliorating, or slowing progression of cancer. In certain embodiments, the cancer is associated with an immunosuppressive microenvironment or stroma.



WO 2020/102558 A1